DEXCOM INC DXCM
Surgical & Medical Instruments & Apparatus · Nasdaq
Revenue
$3.62B
+24.5% YoY
Net income
$541.50M
+58.7% YoY
Total assets
$6.48B
+3.5% YoY
EPS
1.30
+58.5% YoY
Advertisement
Income Statement
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $3.40B | $2.19B | $1.04B | $3.62B | $2.92B | $1.93B | $921.00M | $2.91B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | $2.01B | $1.28B | $589.00M | $2.29B | $1.78B | $1.19B | $561.90M | $1.88B |
| R&D Expense | $450.90M | $293.40M | $145.20M | $505.80M | $412.90M | $277.50M | $141.50M | $484.20M |
| SG&A Expense | $969.50M | $638.10M | $310.10M | $1.19B | $958.40M | $652.00M | $319.30M | $1.01B |
| Operating Income (Loss) | $588.80M | $346.30M | $133.70M | $597.70M | $411.10M | $259.10M | $101.10M | $391.20M |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $569.00M | $285.20M | $105.40M | $541.50M | $424.50M | $289.90M | $146.40M | $341.20M |
| EPS (Diluted) | 1.42 | 0.71 | 0.27 | 1.30 | 1.04 | 0.71 | 0.36 | 0.82 |
Balance Sheet
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.34B | $6.34B | $6.34B | $6.48B | $6.48B | $6.48B | $6.48B | $6.26B |
| Current Assets | $4.03B | $4.03B | $4.03B | $4.30B | $4.30B | $4.30B | $4.30B | $4.43B |
| Cash & Equivalents | $1.84B | $1.16B | $904.90M | $566.30M | $621.20M | $939.20M | $851.20M | $642.30M |
| Accounts Receivable | $1.22B | $1.22B | $1.22B | $1.01B | $1.01B | $1.01B | $1.01B | $973.90M |
| Inventory | $629.10M | $629.10M | $629.10M | $542.60M | $542.60M | $542.60M | $542.60M | $559.60M |
| PP&E (Net) | — | — | — | — | — | — | — | — |
| Goodwill | $24.20M | $24.20M | $24.20M | $22.80M | $22.80M | $22.80M | $22.80M | $25.20M |
| Total Liabilities | $3.59B | $3.59B | $3.59B | $4.38B | $4.38B | $4.38B | $4.38B | $4.20B |
| Current Liabilities | $2.14B | $2.14B | $2.14B | $2.93B | $2.93B | $2.93B | $2.93B | $1.56B |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Stockholders Equity | $2.10B | $2.10B | $2.10B | $2.13B | $2.07B | $2.07B | $2.07B | $2.04B |
Cash Flow Statement
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.15B | $486.80M | $183.80M | $748.50M | $688.10M | $488.60M | $209.20M | $669.50M |
| Investing Cash Flow | $229.40M | $36.60M | $100.20M | $-507.20M | $96.20M | $-114.10M | $74.80M | $-521.50M |
| Financing Cash Flow | $-164.20M | $10.80M | $12.50M | $-318.60M | $-733.20M | $3.30M | $4.70M | $-552.50M |
| Stock Repurchases | $187.20M | $0 | — | $688.70M | $750.00M | — | — | $557.70M |
Similar companies
BAXTER INTERNATIONAL INC
BAX
BECTON DICKINSON & CO
BDX
BOSTON SCIENTIFIC CORP
BSX
3M CO
MMM
INSULET CORP
PODD
RESMED INC
RMD
Solventum Corp
SOLV
STRYKER CORP
SYK
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.